In the journey from an early molecule of interest to a pre-clinical candidate, the abundance of tools and technologies available to biopharmaceutical researchers ultimately generates a complex landscape of information that requires careful analysis to define a best way forward to the clinic. Viewing this endeavor as a series of collaborative interactions is a critical first step in the design and execution of a program plan that will ultimately result in the delivery of a medicine of value to patients. Collaborative Pharma Consulting, LLC (CPC, LLC) can provide critical guidance and analysis frameworks to drive the process of evaluating disease relevant pathways, target tractability and modality options for a defined therapeutic area. The overall objective is to build, as early as possible, confidence in the selected approach to generate a therapeutic agent for a specific disease indication. Decisions made during the early stages of a project can have huge impact on the progress of a molecule towards the clinic.